Embracing inclusion in Multiple Sclerosis research

No one likes to be left out. Feeling excluded is the worst. It leaves you feeling such doubt. Wondering why was I ignored or overlooked? More often than not, it’s not you, it’s them. Seriously! They’re the problem, not you.

Speaking of problems, I will do pretty much whatever it takes to figure out my life’s biggest problem: Multiple Sclerosis. I imagine most other people living with this chronic disease of the central nervous system feel the same way. MS is a horrible disease, and I want to fundraise, educate people and be included as part of the reason this mystery is one day solved and we find a way to stop MS.

Thankfully, we are getting closer. Over the past two decades, researchers have made significant progress in understanding MS and even have developed numerous new treatments to slow its progression.

But, remember my earlier comment about how bad it feels to be left out? Imagine being a person of color and learning that you weren’t represented in the clinical research that led to the treatment’s approval.

That’s how it can feel for minorities who historically have been underrepresented in MS research.

MS affects everyone who is living with it differently (just look at Dan and me). The age of onset, how fast the disease progresses, and the severity of symptoms vary widely from person to person.

This is why it is so important that Genentech initiated the first-ever clinical trial that focuses exclusively on broadening our current understanding of MS disease biology among people who identify as Black or of African descent and Hispanic/Latinos living with MS. The Phase IV CHIMES study, or CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis, currently is enrolling participants across the United States.

Genentech reports that minority communities living with MS, including people who identify as Black or of African descent and Hispanic/Latinos, experience more severe symptoms and a faster progression of the disease than their Caucasian counterparts. People who identify as Black or of African descent also have twice the risk of MS compared to Caucasians, while people who identify as Hispanic/Latinos have half the risk.

Such underrepresentation leads to limited data on the progression of MS, the effectiveness of treatment, and its genetic underpinnings. It also excludes people living with this condition from an opportunity to receive treatments that have the potential to make a difference.

Dan and I were thrilled to see that this effort includes the perspective of two powerful voices in the MS community: Dr. Mitzi Joi Williams, a neurologist at Joi Life Wellness MS Center, and our friend Damian Washington, an MS patient leader and vlogger we recently chatted with for our 7 Questions with A Couple feature.

Hear what they have to say about this important work:

Leave a Reply

Your email address will not be published. Required fields are marked *